Loading...
•
Mar 31
Ginkgo Bioworks Q1 2025 Earnings Report
reported first quarter 2025 financial results, including progress towards its expanded $250 million cost savings target and a $29 million contract awarded by ARPA-H
Key Takeaways
Ginkgo Bioworks reported a net loss of $90.957 million in Q1 2025, an improvement from the $165.911 million net loss in Q1 2024. Total revenue increased to $48.318 million, driven by a significant increase in Cell Engineering revenue.
Net loss decreased significantly from $165.911 million in Q1 2024 to $90.957 million in Q1 2025.
Total revenue increased by approximately 27.4% to $48.318 million in Q1 2025.
Cell Engineering revenue saw substantial growth, increasing from $27.889 million in Q1 2024 to $38.230 million in Q1 2025.
Cash and cash equivalents decreased to $312.420 million as of March 31, 2025, compared to $561.572 million as of December 31, 2024.
Ginkgo Bioworks
Ginkgo Bioworks
Ginkgo Bioworks Revenue by Segment
Revenue by Segment
Cell Engineering Revenue
CapyFin.comBiosecurity Revenue
CapyFin.com Forward Guidance
The report mentions full year 2025 guidance is available in the webcast presentation and supplemental financial information, but does not provide specific figures in the text.
Positive Outlook
- Progress towards expanded $250 million cost savings target.
- Solutions business becoming a trusted R&D service provider.
- Tools businesses have traction with existing offerings.
- Tools businesses are positioned to meet emergent opportunities in areas like AI.
- Awarded $29 million contract by ARPA-H.
Challenges Ahead
- Specific forward guidance figures were not included in the press release text.
- Reliance on webcast for detailed outlook.
- Continued net loss in the current quarter.